All In Biotech

Drug Trial Radar · NCT00683111

Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Planned (sponsor's estimate)

Start

Jul 2008

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Ruttonjee HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aspirin and clopidogrel +/- heparin or thrombolytic co-therapy is well established and effective treatment for unstable cardiac patients. However, the major complication was gastrointestinal bleeding (GIB) due to peptic ulcer. In the prevention of GIB, anti-ulcer drug either H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) were commonly prescribed. There has been no prospective controlled study to compare the efficacy of these two classes of anti-ulcer drugs.

Conditions

  • Acute Coronary Syndrome
  • Acute Myocardial Infarction

Interventions

  • esomeprazole 20 mg dailyDrug

    oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months

  • famotidine 40 mg dailyDrug

    oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ulcer complication (bleeding/perforation/obstruction)Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruttonjee Hospital

    Hong Kong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.